Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 5Breast Neoplasms 4Vomiting 3Neoplasms 3Lymphoma, Non-Hodgkin 3Stomach Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasm Metastasis 2Nausea 2Hodgkin Disease 2Hematologic Neoplasms 2Endometrial Neoplasms 2Burkitt Lymphoma 2Uterine Cervical Neoplasms 1Stomatitis 1Squamous Cell Carcinoma of Head and Neck 1Renal Insufficiency 1Rectal Neoplasms 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Postoperative Nausea and Vomiting 1Pathologic Complete Response 1Paraproteinemias 1Pain 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms by Histologic Type 1NSCLC 1Mucositis 1Mastocytosis, Systemic 1

Interventions

Cyclophosphamide 4Gemcitabine 3isatuximab 2entrectinib 2cobimetinib 2capmatinib 2atezolizumab 2anlotinib 2alectinib 2Vemurafenib 2Sunitinib 2Rituximab 2Lenalidomide 2Dexamethasone 2Cisplatin 2trametinib 1spartalizumab 1pomalidomide 1pertuzumab 1penpulimab 1pembrolizumab 1olaparib 1niraparib 1lutetium Lu 177 dotatate 1ibritumomab tiuxetan 1fludarabine 1dabrafenib 1copper dotatate CU-64 1Trastuzumab 1Taxes 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Neoplasms by Histologic Type × Diphenhydramine × Clear all
NCT05298683 2022-03-28

A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor

Hellenic Society of Hematology

Phase 2 Unknown
108 enrolled
Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Renal Insufficiency, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡